Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study (Q45305137)

11 December 2017

title

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study (English)

1 reference

11 December 2017

main subject

pulmonary hypertension

1 reference

10

Dudley J Pennell

1 reference

11 December 2017

9

Leong L Ng

1 reference

11 December 2017

Martin R Wilkins

1

1 reference

11 December 2017

Gideon A Paul

2

1 reference

11 December 2017

Julian W Strange

3

1 reference

11 December 2017

Nina Tunariu

4

1 reference

11 December 2017

Wendy Gin-Sing

5

1 reference

11 December 2017

Winston A Banya

6

1 reference

11 December 2017

Mark A Westwood

7

1 reference

11 December 2017

Alexander Stefanidis

8

1 reference

11 December 2017

Raad H Mohiaddin

11

1 reference

11 December 2017

Petros Nihoyannopoulos

12

1 reference

11 December 2017

J Simon R Gibbs

13

1 reference

11 December 2017

language of work or name

English

0 references

publication date

4 March 2005

1 reference

American Journal of Respiratory and Critical Care Medicine

11 December 2017

published in

1 reference

11 December 2017

volume

171

1 reference

11 December 2017

issue

11

1 reference

11 December 2017

page(s)

1292-1297

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Distribution of endothelin-like immunoreactivity and mRNA in the developing and adult human lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Cyclic GMP phosphodiesterase-5: target of sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Cyclic GMP phosphodiesterases and regulation of smooth muscle function

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Sildenafil inhibits hypoxia-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Breath-hold FLASH and FISP cardiovascular MR imaging: left ventricular volume differences and reproducibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Atrial Volume in a Normal Adult Population by Two-dimensional Echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Doppler echocardiographic index for assessment of global right ventricular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200410-1411OC

10.1164/RCCM.200410-1411OC

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference